This compound, known as Cefadroxil, is a first-generation cephalosporin antibiotic widely used in the pharmaceutical industry to treat bacterial infections. It is effective against a broad range of gram-positive and some gram-negative bacteria, particularly for respiratory tract infections (e.g., bronchitis, pneumonia, sinusitis), urinary tract infections, skin and soft tissue infections, and pharyngitis or tonsillitis. Cefadroxil acts by inhibiting the synthesis of the bacterial cell wall, leading to cell lysis and death. Its beta-lactam structure provides moderate resistance to beta-lactamase enzymes produced by some bacteria, enhancing its efficacy against certain resistant strains. Due to its chiral centers and functional groups, including the 4-hydroxyphenyl side chain, it offers good oral bioavailability, stability, and pharmacokinetics. It is primarily formulated as oral capsules, tablets, or suspensions for patient convenience.